RT Journal Article
SR Electronic
T1 Polygenic risk score from a multi-ancestry GWAS uncovers susceptibility of heart failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.06.21267389
DO 10.1101/2021.12.06.21267389
A1 Kuan-Han H. Wu
A1 Nicholas J. Douville
A1 Matthew C. Konerman
A1 Michael R. Mathis
A1 Scott L. Hummel
A1 Brooke N. Wolford
A1 Ida Surakka
A1 Sarah E. Graham
A1 Hyeon Joo
A1 Jibril Hirbo
A1 Nancy J. Cox
A1 Simon Lee
A1 Michael Preuss
A1 Ruth J.F. Loos
A1 Mark J. Daly
A1 Benjamin M. Neale
A1 Wei Zhou
A1 Whitney E. Hornsby
A1 Cristen. J. Willer
A1 on behalf of the Global Biobank Meta-analysis Initiative
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.06.21267389.abstract
AB Identifying individuals at high risk of heart failure during precursor stages could allow for earlier initiation of treatments to modify disease progression. We performed a GWAS meta- analysis to generate a heart failure (HF) polygenic risk score (PRS) then tested the association with phenotypic subtypes (reduced ejection fraction [HFrEF] and preserved ejection fraction [HFpEF]) to evaluate the value of polygenic risk prediction. Results from the European-ancestry analysis showed that an ancestry-matched PRS, calculated from GBMI meta-analysis outperformed the previous HF GWAS (HERMES), yielding an adjusted odds ratio (aOR) of 2.27 (95% CI: 2.05-2.51; p: 1.76×10−56) from GBMI compared to 1.30 (95% CI: 1.18-1.44; p: 1.42×10− 7) from HERMES, and 1.49 (95% CI: 1.33-1.66; p: 8.38×10−13) compared to 1.17 (95% CI: 1.05- 1.31; p: 0.004) for HFrEF and HFpEF, respectively. Next, we evaluated the performance differences between ancestry-matched and multi-ancestry PRS in the African American cohort. The GBMI multi-ancestry GWAS-based PRS had a significant aOR of 1.49 (p: 0.006). Findings suggest that a PRS for heart failure derived from the GBMI multi-ancestry study is useful in predicting HFrEF, but less powerful in predicting HFpEF in an independent cohort. The difficulty in predicting HFpEF could result from the GBMI HF phenotype, preferencing HFrEF over HFpEF, and/or greater genetic heterogeneity in the HFpEF phenotype.Competing Interest StatementThe spouse of C.J.W. works at Regeneron pharmaceuticals. M.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. M.R.M. has received a research grant from the US National Institutes of Health (K01-HL141701), Bethesda, MD.Funding StatementDr. Willer is supported by National Institutes of Health grants R35-HL135824, R01-HL142023, R01-DK075787, and R01-HL109946Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of The University of Michigan approved these protocols (HUM00128472 and HUM00052866) and all study participants signed informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMeta-analysis conducted by Global Biobank Meta-analysis Initiative are available online at http://results.globalbiobankmeta.org/ http://results.globalbiobankmeta.org/